State Disciplines Psychiatrist For Improper Prescription Monitoring, Excessive Drinking

The Medical Examining Board issued this week a four-year probationary period to a psychiatrist who is accused of excessive drinking and failing to follow state law on utilizing Connecticut’s prescription monitoring program. Department of Public Health (DPH) investigators determined that Dr. Susannah Tung, a psychiatrist, who runs a private practice while also working for the state Department of Correction (DOC), abused alcohol to excess at least twice; on Oct. 11 2017 and Feb. 20, 2020. The board, in addition to the probation, reprimanded Tung’s license.

Handful Of High Prescribers Boost Medicare Spending, New Data Show

Ten Connecticut prescribers, including a Derby nurse practitioner who is under investigation by the state, were responsible for more than 22 percent of the state’s Medicare spending on potent narcotics in 2013, new federal data show. More than 4,300 Connecticut clinicians, mostly physicians, wrote Medicare prescriptions for oxycodone, morphine and other Schedule II drugs, which have a high potential for abuse and addiction, at a total cost of $40 million. But a handful of those providers accounted for the largest share of those prescriptions, an analysis of the data show. Topping the list, in both the number of prescriptions and cost, was Heather Alfonso, an advanced practice registered nurse (APRN) at the Comprehensive Pain & Headache Treatment Centers, LLC, in Derby, who wrote out 8,523 prescriptions, at a cost of $2.7 million. Statewide, the average number of prescriptions per clinician was 104, and no other prescriber had more than 5,000 Schedule II claims. The average cost per prescriber was $9,138; the next closest individual cost was $1.8 million.

CT Joins $90 Million Settlement with GlaxoSmithKline

The state will receive $1.6 million as part of a $90 million multi-state settlement with the drug maker GlaxoSmithKline to resolve allegations that the company unlawfully promoted its diabetes drug, Avandia. Thirty-seven other states are participating in the settlement, following claims that GlaxoSmithKline (GSK) engaged in unfair and deceptive practices by misrepresenting Avandia’s potential cardiovascular risks and by promoting the drug to physicians and other healthcare professionals with false and misleading representations about Avandia’s safety profile. The settlement resolves the state’s claim against the company under the Connecticut Unfair Trade Practices Act. Connecticut’s share of the settlement is $1,668,482, of which $100,000 will be allocated to the Department of Consumer Protection to support the Prescription Drug Monitoring Program and the agency’s Consumer Fund. Another $100,000 will go to the Attorney General’s Consumer Fund.